Attached files
file | filename |
---|---|
EX-31.1 - EX-31.1 - Landos Biopharma, Inc. | labp-20210331-ex31_1.htm |
10-Q - 10-Q - Landos Biopharma, Inc. | labp-20210331.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Landos Biopharma, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
Date: May 17, 2021 |
|
By: |
/s/ Josep Bassaganya-Riera |
|
|
|
Josep Bassaganya-Riera |
|
|
|
Chairman, President, and Chief Executive Officer |